Multinational pharmaceutical, biotechnology and medical technologies company Johnson & Johnson (NYSE: JNJ) announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for its TREMFYA (guselkumab) intended to treat adults with moderately to severely active ulcerative colitis (UC).
The product is the first and only approved fully-human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.
The approval of the product is based on data from a pivotal, ongoing Phase 2b/3 QUASAR study assessing the efficacy and safety of TREMFYA in adult patients who experienced an inadequate response or who showcase intolerance to conventional therapy, other biologics and/or JAK inhibitors.
David T Rubin, MD, director, Inflammatory Bowel Disease Center, University of Chicago Medicine and lead investigator for the QUASAR programme, said, 'Treatment with TREMFYA resulted in significant improvement in the chronic symptoms of ulcerative colitis, and importantly, normalization in the endoscopic appearance of the intestinal lining. Today's approval of TREMFYA builds on the clinical and well-established safety profile of this IL-23 inhibitor and marks a significant step forward in the treatment of this chronic inflammatory disease.'
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Pfizer names new Regional President for Middle East, Russia and Africa
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Lipella launches OLP Patient Registry to advance research
Talphera enrols first subject in NEPHRO CRRT study
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Cantargia reports positive CAN10 trial data
Quoin Pharmaceuticals to study QRX003 for Peeling Skin Syndrome
Dragonfly Therapeutics names new chief financial officer
Formosa Pharmaceuticals secures exclusive Canadian licensing deal with Apotex
Bio-Techne invests in Spear Bio to boost ultra-sensitive immunoassay development